March 22, 2024
Iron overload occurs due to excessive iron intake compared to the body’s demand, leading to iron deposition and impairment of multiple organ functions. Our previous study demonstrated that chronic oral administration of ferric citrate (FC) caused colonic inflammatory injury. However, the precise mechanism underlying this inflammatory response remains unclear.
Investigation the mechanism of iron overload-induced colonic inflammation following ferric citrate exposure
March 22, 2024
Tuberculosis (TB) continues to be a global public health crisis, responsible for 1.4 million deaths in 2021 alone [1]. TB is caused by Mycobacterium tuberculosis (Mtb). Mtb is introduced to its host upon inhalation of contaminated respiratory droplets, allowing direct entry into the lungs. Bacteria are deposited in the well-ventilated lower lobes of the lung, where alveolar macrophages phagocytose them [2]. Mtb is subsequently able to survive and replicate within the endosomes of these macrophages [3]. As the infection progresses, infected macrophages release chemokines and cytokines, which recruit other immune cells (e.g., monocytes, T cells, B cells, NK cells, dendritic cells, and neutrophils) to form a granuloma. A granuloma is generally comprised of a core of infected macrophages, surrounded by monocytes, epithelioid macrophages, foamy macrophages, neutrophils, multinucleated giant cells, and finally a lymphocytic cuff with an outer fibrous capsule [4]. The timing and spatial organization of key host-pathogen interactions within these granuloma structures, and how these interactions contribute to bacterial survival or elimination, remains incompletely understood.
In silico agent-based modeling approach to characterize multiple in vitro tuberculosis infection models
March 22, 2024
Research teams led by a faculty member in Purdue University’s College of Engineering will use two grants from the National Eye Institute totaling $6.7 million to further develop specialized smart soft contact lenses that continuously monitor or treat chronic ocular diseases like glaucoma, corneal neovascularization and dry eye syndromes. The research teams include Dr. Shin Ae Park, assistant professor of ophthalmology in the Purdue University College of Veterinary Medicine. The teams are led by Dr. Chi Hwan Lee, the Leslie A. Geddes Associate Professor of Biomedical Engineering in Purdue’s Weldon School of Biomedical Engineering. He holds a joint appointment in the School of Mechanical Engineering and a courtesy appointment in the School of Materials Engineering. The research teams are developing patent-pending lenses, which can painlessly deliver therapeutic drugs or accurately measure intraocular pressure, or IOP. IOP is the only known modifiable risk factor for glaucoma.
Purdue Veterinary Ophthalmologist Contributes to Purdue-led Research to Develop Tech to Monitor, Treat Chronic Eye Diseases
March 21, 2024
The American Lung Association in Indiana will honor Purdue University researcher Philip Low on April 13 at its annual gala in Indianapolis for his invention of CYTALUX, which helps in the fight against lung cancer. Low, Purdue’s Presidential Scholar for Drug Discovery and the Ralph C. Corley Distinguished Professor of Chemistry in the College of Science, developed CYTALUX, an FDA-approved fluorescent marker that illuminates lung cancer cells during surgery. This allows surgeons to quickly distinguish malignant cells from healthy cells and confirm that all malignant cells have been removed. Total removal is key to preserving the lives of lung cancer patients.
Low to be honored by American Lung Association for cancer-fighting invention
March 20, 2024
Purdue researcher leads teams creating patent-pending smart contacts for glaucoma, neovascularization and dry eyes
$6.7M in federal grants awarded to develop tech to monitor, treat chronic eye diseases
March 20, 2024
A team of researchers from Purdue University, Indiana University School of Optometry and Michigan Medicine have received two grants totaling $6.7 million from the National Eye Institute to further develop specialized smart soft contact lenses that continuously monitor or treat chronic eye diseases.
Purdue University Chi Hwan Lee specialized smart soft contact lenses
March 20, 2024
Research teams at Purdue have been given $6.7 million in grants from the National Eye Institute to develop smart contact lenses that can detect and treat various vision impairments.
March 12, 2024
Multiple sclerosis (MS) is an inflammatory, demyelinating disease of the brain and spinal cord which affects approximately 2.5 million individuals worldwide, often striking young adults without warning1,2,3,4. Patients experience a variety of motor, sensory, and cognitive deficiencies1,3,5. Unfortunately, due to the incomplete understanding of the etiology of MS, current available therapies remain largely unsatisfactory, as they mainly focus on immunomodulation or symptomatic relief with limited success2. As such, the long-term trajectory and prognosis for most MS patients, a continual worsening of symptoms until death, is not significantly altered by the current standards of care6,7,8,9,10,11. Thus, a major priority in this field is to identify key pathological factors that can provide new and effective therapeutical targets to deter the pathological progression of MS. There is strong evidence that reactive oxygen species are the mediators of MS pathology12,13,14,15,16. However, antioxidant therapeutic strategies alone have shown limited success in mitigating disease progression14,17,18. Recently, emerging scientific findings suggest that reactive aldehydes, products of free radical-instigated lipid peroxidation, may play a critical role in the pathogenesis of MS19,20,21,22,23. Acrolein, a toxic reactive aldehyde, is both a product and catalyst of oxidative stress and inflammation24,25. As such, it can induce a vicious cycle wherein it begets and worsens the mechanisms by which it is created, thereby amplifying its effects24,25,26. Therefore, acrolein may provide a better target to suppress oxidative stress in MS.
Neuroprotection by acrolein sequestration through exogenously applied scavengers and endogenous enzymatic enabling strategies in mouse EAE model
March 9, 2024
Tao and his associates have begun developing a patent-pending EV method for detecting proteins involved in drug absorption, distribution, metabolism and excretion (ADME). “If successful, this would be tremendously beneficial, especially for drug development companies,” Tao said.
Purdue Researchers Investigate Noninvasive Method For Sampling Drug Response
March 9, 2024
Amplified Sciences, a clinical-stage life sciences diagnostic company that licenses Purdue University innovations, has received $108,000 in two investments from the Flywheel Fund to develop its tests for early, more accurate detection of challenging diseases, starting with pancreatic cancer. Amplified Sciences’ diagnostic tests are based on technology invented by V. Jo Davisson, professor of medicinal chemistry and molecular pharmacology in Purdue University’s College of Pharmacy and a faculty member of the Purdue Institute for Cancer Research and the Purdue Institute for Drug Discovery. Davisson serves as the company’s chief scientific officer. The company licenses Davisson’s intellectual property through the Purdue Innovates Office of Technology Commercialization.
Purdue University: Amplified Sciences Secures $108K Flywheel Fund Investment For Development Of Pancreatic Cancer Diagnostics
